Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Dec 30;33(2):E76–E80. doi: 10.1002/clc.20511

Epidemiological Association between Uric Acid Concentration in Plasma, Lipoprotein(a), and the Traditional Lipid Profile

Giuseppe Lippi 1, Martina Montagnana 1, Gian Luca Salvagno 1,✉, Giovanni Targher 2, Gian Cesare Guidi 1
PMCID: PMC6653668  PMID: 20043336

Abstract

Background

Elevated levels of uric acid in serum (SUA) or plasma (PUA) are increasingly related to cardiovascular disease. It is unclear whether they are independent risk factors or simply markers, reflecting association with other traditional risk factors.

Methods

We retrospectively assessed results of a lipid profile, including total cholesterol, low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), triglycerides, total cholesterol to HDL‐C ratio (TC/HDL‐C), the atherogenic index of plasma (AIP), and lipoprotein(a) (Lp[a]), in a large cohort of unselected adult outpatients.

Results

Hyperuricemic men displayed significantly increased values of triglycerides and AIP when compared with men with normal PUA levels. In hyperuricemic women, significant differences were observed for HDL‐C, triglycerides, TC/HDL‐C, and AIP compared with women with normal PUA levels. The percentage of patients with unfavorable values was statistically higher for triglycerides and AIP in hyperuricemic men; for HDL‐C, triglycerides, TC/HDL‐C, and AIP in hyperuricemic women. In multivariable linear regression analysis triglycerides, AIP, and TC/HDL‐C were independently associated with PUA in women, whereas no significant association was observed in men.

Conclusion

PUA measurement might be advisable in patients to identify those at increased risk of cardiovascular disease (CVD) who might benefit from further triage and intervention. Copyright © 2010 Wiley Periodicals, Inc.

Keywords: uric acid, hyperglycemia, hypertriglyceridemia, lipoprotein(a)

Full Text

The Full Text of this article is available as a PDF (108.8 KB).

References

  • 1. Giesecke D, Tiemeyer W. Defect of uric acid uptake in Dalmatian dog liver. Experientia 1984; 40: 1415–1416. [DOI] [PubMed] [Google Scholar]
  • 2. Doumas BT, Hause LL, Simuncak DM, Breitenfeld D. Differences between values for plasma and serum in tests performed in the Ektachem 700 XR Analyzer, and evaluation of “plasma separator tubes (PST).” Clin Chem 1989; 35: 151–153. [PubMed] [Google Scholar]
  • 3. Ciuti R, Rinaldi G. Serum and plasma compared for use in 19 common chemical tests performed in the Hitachi 737 analyzer. Clin Chem 1989; 35: 1562–1563. [PubMed] [Google Scholar]
  • 4. Nath SD, Voruganti VS, Arar NH, et al. Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol 2007; 18: 3156–3163. [DOI] [PubMed] [Google Scholar]
  • 5. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow‐up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404–2410. [DOI] [PubMed] [Google Scholar]
  • 6. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18: 287–292. [DOI] [PubMed] [Google Scholar]
  • 7. Chien KL, Chen MF, Hsu HC, et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 2008; 54: 310–316. [DOI] [PubMed] [Google Scholar]
  • 8. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421–1431. [DOI] [PubMed] [Google Scholar]
  • 9. Kohn PM, Prozan GB. Hyperuricemia—relationship to hypercholesteremia and acute myocardial infarction. JAMA 1959; 170: 1909–1912. [DOI] [PubMed] [Google Scholar]
  • 10. Beard JT. Serum uric acid and coronary heart disease. Am Heart J 1983; 106: 397–400. [DOI] [PubMed] [Google Scholar]
  • 11. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89: 12–17. [DOI] [PubMed] [Google Scholar]
  • 12. Madsen TE, Muhlestein JB, Carlquist JF, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005; 25: 45–49. [DOI] [PubMed] [Google Scholar]
  • 13. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928–933. [DOI] [PubMed] [Google Scholar]
  • 14. Johnson RJ, Feig DI, Herrera‐Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45: 18–20. [DOI] [PubMed] [Google Scholar]
  • 15. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127: 321–336. [DOI] [PubMed] [Google Scholar]
  • 16. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta In press. [DOI] [PubMed] [Google Scholar]
  • 17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502. [PubMed] [Google Scholar]
  • 18. Dobiasova M. Atherogenic index of plasma [log(triglycerides/ HDL‐cholesterol)]: theoretical and practical implications. Clin Chem 2004; 50: 1113–1115. [DOI] [PubMed] [Google Scholar]
  • 19. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple‐risk‐factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481–1492. [DOI] [PubMed] [Google Scholar]
  • 20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497. [DOI] [PubMed] [Google Scholar]
  • 21. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout—influence of alcohol intake and body weight. Br J Rheumatol 1994; 33: 731–734. [DOI] [PubMed] [Google Scholar]
  • 22. Jiao S, Kameda K, Matsuzawa Y, Tarui S. Hyperlipoproteinaemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan. Ann Rheum Dis 1986; 45: 308–313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Gibson T, Grahame R. Gout and hyperlipidaemia. Ann Rheum Dis 1974; 33: 298–303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Naito HK, Mackenzie AH. Secondary hypertriglyceridemia and hyperlipoproteinemia in patients with primary symptomatic gout. Clin Chem 1979; 25: 371–375. [PubMed] [Google Scholar]
  • 25. Gibson T, Kilbourn K, Horner I, Simmonds HA. Mechanism and treatment of hypertriglyceridaemia in gout. Ann Rheum Dis 1979; 3: 31–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Cardona F, Tinahones FJ, Collantes E, Escudero A, Garcia‐Fuentes E, Soriguer FJ. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology 2003; 42: 469–472. [PubMed] [Google Scholar]
  • 27. Fox IH, John D, DeBruyne S, Dwosh I, Marliss EB. Hyperuricemia and hypertriglyceridemia: metabolic basis for the association. Metabolism 1985; 34: 741–746. [DOI] [PubMed] [Google Scholar]
  • 28. Vuorinen‐Markkola H, Yki‐Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994; 78: 25–29. [DOI] [PubMed] [Google Scholar]
  • 29. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA Study. Ann Epidemiol 1998; 8: 250–261. [DOI] [PubMed] [Google Scholar]
  • 30. Clausen JO, Borch‐Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population‐based sample of 380 young healthy Caucasians. Eur J Endocrinol 1998; 138: 63–69. [DOI] [PubMed] [Google Scholar]
  • 31. Onat A, Uyarel H, Hergenç G, et al. Serum uric acid is a determinant of metabolic syndrome in a population‐based study. Am J Hypertens 2006; 19: 1055–1062. [DOI] [PubMed] [Google Scholar]
  • 32. Chu NF, Wang DJ, Liou SH, Shieh SM. Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. Eur J Epidemiol 2000; 16: 13–17. [DOI] [PubMed] [Google Scholar]
  • 33. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc 2006; 69: 512–516. [DOI] [PubMed] [Google Scholar]
  • 34. Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401–410. [DOI] [PubMed] [Google Scholar]
  • 35. Collantes Estevéz E, Tinahones Madueño FJ, González Ruiz A, Añón Barbudo J, Pineda Priego M, Sánchez Guijo P. Renal excretion of urate by hyperuricaemic‐hyperlipidemic patients. Clin Rheumatol 1992; 11: 498–501. [DOI] [PubMed] [Google Scholar]
  • 36. Tinahones JF, Perez‐Lindon G, Soriguer FJ, et al. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic‐hypertrigly‐ ceridemic patients. J Clin Endocrinol Metab 1997; 82: 1188–1191. [DOI] [PubMed] [Google Scholar]
  • 37. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis 1995; 54: 90–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003; 40: 1–42. [DOI] [PubMed] [Google Scholar]
  • 39. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 2006; 62: 633–664. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES